BACKGROUND: Since cyclosporine A has been used in clinical, the survival rate of transplanted kidney have been significantly improved, but renal toxicity, hypertension, hyperlipidemia and other adverse reactions subsequently, increased the incidence of rejection.
OBJECTIVE: To evaluate the effect of Tacrolimus on renal function, blood fat, and blood pressure of patients following renal transplantation.
METHODS: A total of 35 patients with allograft renal transplantation, including 21 males and 14 females, average aging (38.3±22.6) years, were selected from People’s Hospital of Zhengzhou. All received the immunosuppressive regimen of cyclosporine A, mycophenolate mofetil, and prednisone. Transplantation time was 27 (11-53) months, and serum creatinine level was 134.4-232.8 µmol/L. Following one-year following up, blood pressure of 12 patients was up to 140/90 mm Hg (1 mm Hg= 0.133 kPa), 6 patients had hypertrichosis and gingival hyperplasia, and 17 patients had hyperlipoidemia. After stopping taking cyclosporin A, mycophenolate mofetil was adjusted to 750 mg, and administrated twice a day. Two days later, tacrolimus (0.10-0.15 mg/kg) was additionally given. According to serum concentration, the dose was adjusted correspondingly. Serum creatinine (SCr), glomerular filtration rate (GFR), 24-hour urinary protein, blood lipids and other biochemical parameters were monitored, and the adverse drug reactions were observed during the following-up.
RESULTS AND CONCLUSION: A total of 32 out of 35 patients finished the one-year following up. Two patients were given cyclosporine A due to diabetes mellitus and moderate alopecia, and one patient was lost during following up. After 1 year, blood pressure of 12 patients was improved remarkably (P < 0.05), and blood fat level of most patients significantly decreased, including the level of 7 patients was normal. Additionally, hypertrichosis and gingival hyperplasia of 6 patients were improved obviously, and diabetes mellitus or aggravation was not checked out after change of dressing. Serum creatinine (SCr) and urea nitrogen clearance ratio of all patients were significantly improved (P < 0.05). This suggested that tacrolimus remarkably improved cardio-cerebral vessel and renal function, and relieved or eliminated adverse effects.